Literature DB >> 25452394

TERT promoter mutation designates biologically aggressive primary glioblastoma.

Jason T Huse1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25452394      PMCID： PMC4483057          DOI： 10.1093/neuonc/nou318

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

1.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

2.  TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.

Authors:  Matthias Simon; Ismail Hosen; Konstantinos Gousias; Sivaramakrishna Rachakonda; Barbara Heidenreich; Marco Gessi; Johannes Schramm; Kari Hemminki; Andreas Waha; Rajiv Kumar
Journal:  Neuro Oncol       Date:  2014-08-18       Impact factor: 12.300

3.  ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.

Authors:  Benedikt Wiestler; David Capper; Tim Holland-Letz; Andrey Korshunov; Andreas von Deimling; Stefan Michael Pfister; Michael Platten; Michael Weller; Wolfgang Wick
Journal:  Acta Neuropathol       Date:  2013-08-01       Impact factor: 17.088

4.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Authors:  Patrick J Killela; Zachary J Reitman; Yuchen Jiao; Chetan Bettegowda; Nishant Agrawal; Luis A Diaz; Allan H Friedman; Henry Friedman; Gary L Gallia; Beppino C Giovanella; Arthur P Grollman; Tong-Chuan He; Yiping He; Ralph H Hruban; George I Jallo; Nils Mandahl; Alan K Meeker; Fredrik Mertens; George J Netto; B Ahmed Rasheed; Gregory J Riggins; Thomas A Rosenquist; Mark Schiffman; Ie-Ming Shih; Dan Theodorescu; Michael S Torbenson; Victor E Velculescu; Tian-Li Wang; Nicolas Wentzensen; Laura D Wood; Ming Zhang; Roger E McLendon; Darell D Bigner; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Hai Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

5.  TERT promoter mutations in familial and sporadic melanoma.

Authors:  Susanne Horn; Adina Figl; P Sivaramakrishna Rachakonda; Christine Fischer; Antje Sucker; Andreas Gast; Stephanie Kadel; Iris Moll; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

6.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

7.  TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.

Authors:  P Sivaramakrishna Rachakonda; Ismail Hosen; Petra J de Verdier; Mahdi Fallah; Barbara Heidenreich; Charlotta Ryk; N Peter Wiklund; Gunnar Steineck; Dirk Schadendorf; Kari Hemminki; Rajiv Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

Review 8.  The molecular landscape of diffuse glioma and prospects for biomarker development.

Authors:  Jason T Huse; Kenneth D Aldape
Journal:  Expert Opin Med Diagn       Date:  2013-10-28

9.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

Authors:  Yuchen Jiao; Patrick J Killela; Zachary J Reitman; Ahmed B Rasheed; Christopher M Heaphy; Roeland F de Wilde; Fausto J Rodriguez; Sergio Rosemberg; Sueli Mieko Oba-Shinjo; Suely Kazue Nagahashi Marie; Chetan Bettegowda; Nishant Agrawal; Eric Lipp; Christopher Pirozzi; Giselle Lopez; Yiping He; Henry Friedman; Allan H Friedman; Gregory J Riggins; Matthias Holdhoff; Peter Burger; Roger McLendon; Darell D Bigner; Bert Vogelstein; Alan K Meeker; Kenneth W Kinzler; Nickolas Papadopoulos; Luis A Diaz; Hai Yan
Journal:  Oncotarget       Date:  2012-07

10.  Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.

Authors:  Kasthuri Kannan; Akiko Inagaki; Joachim Silber; Daniel Gorovets; Jianan Zhang; Edward R Kastenhuber; Adriana Heguy; John H Petrini; Timothy A Chan; Jason T Huse
Journal:  Oncotarget       Date:  2012-10
  10 in total
  3 in total

1.  Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme.

Authors:  Da Eun Jeong; Seon Rang Woo; Hyun Nam; Do-Hyun Nam; Jae-Ho Lee; Kyeung Min Joo
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

2.  TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms.

Authors:  Seungjae Lee; Raymond L Barnhill; Reinhard Dummer; James Dalton; Jianrong Wu; Alberto Pappo; Armita Bahrami
Journal:  Sci Rep       Date:  2015-06-10       Impact factor: 4.379

3.  Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma.

Authors:  Ashleigh C McEvoy; Leslie Calapre; Michelle R Pereira; Tindaro Giardina; Cleo Robinson; Muhammad A Khattak; Tarek M Meniawy; Antonia L Pritchard; Nicholas K Hayward; Benhur Amanuel; Michael Millward; Melanie Ziman; Elin S Gray
Journal:  Oncotarget       Date:  2017-08-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.